<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS134243</article-id>
<article-id pub-id-type="doi">10.1101/2021.08.30.458295</article-id>
<article-id pub-id-type="archive">PPR389593</article-id>
<article-version article-version-type="publisher-id">1</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Weakly activated core inflammation pathways were identified as a central signaling mechanism contributing to the chronic neurodegeneration in Alzheimer’s disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Fuhai</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A8">8</xref>
<xref ref-type="corresp" rid="CR1">#</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Eteleeb</surname>
<given-names>Abdallah</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A7">7</xref>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Buchser</surname>
<given-names>William</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Guoqiao</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xiong</surname>
<given-names>Chengjie</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Payne</surname>
<given-names>Philip R.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McDade</surname>
<given-names>Eric</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Karch</surname>
<given-names>Celeste M.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A7">7</xref>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Harari</surname>
<given-names>Oscar</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A7">7</xref>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cruchaga</surname>
<given-names>Carlos</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A6">6</xref>
<xref ref-type="aff" rid="A7">7</xref>
<xref ref-type="aff" rid="A8">8</xref>
<xref ref-type="corresp" rid="CR1">#</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Institute for Informatics (I2), Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA</aff>
<aff id="A2">
<label>2</label>Department of Pediatrics, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA</aff>
<aff id="A3">
<label>3</label>Department of Psychiatry, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA</aff>
<aff id="A4">
<label>4</label>Department of Neuroscience, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA</aff>
<aff id="A5">
<label>5</label>Division of Biostatistics, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA</aff>
<aff id="A6">
<label>6</label>Department of Neurology, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA</aff>
<aff id="A7">
<label>7</label>Hope Center for Neurological Disorders, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA</aff>
<aff id="A8">
<label>8</label>NeuroGenomics and Informatics, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA</aff>
<author-notes>
<corresp id="CR1">
<label>#</label>Corresponding : <email>fuhai.li@wustl.edu</email>; <email>cruchagac@wustl.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>08</day>
<month>09</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="preprint">
<day>01</day>
<month>09</month>
<year>2021</year>
</pub-date>
<permissions>
<ali:free_to_read/>
<license>
<ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p>
</license>
</permissions>
<abstract>
<p id="P1">Neuro-inflammation signaling has been identified as an important hallmark of Alzheimer’s disease (AD) in addition to amyloid β plaques (Aβ) and neurofibrillary tangles (NFTs). However, our knowledge of neuro-inflammation is very limited; and the core signaling pathways associated with neuro-inflammation are missing. From a novel perspective, i.e., investigating weakly activated molecular signals (rather than the strongly activated molecular signals), in this study, we uncovered the core neuro-inflammation signaling pathways in AD. Our novel hypothesis is that weakly activated neuro-inflammation signaling pathways can cause neuro-degeneration in a chronic process; whereas, strongly activated neuro-inflammation often cause acute disease progression like in COVID-19. Using the two large-scale genomics datasets, i.e., Mayo Clinic (77 control and 81 AD samples) and RosMap (97 control and 260 AD samples), our analysis identified 7 categories of signaling pathways implicated on AD and related to virus infection: immune response, x-core signaling, apoptosis, lipid dysfunctional, biosynthesis and metabolism, and mineral absorption signaling pathways. More interestingly, most of genes in the virus infection, immune response and x-core signaling pathways, are associated with inflammation molecular functions. Specifically, the x-core signaling pathways were defined as a group of 9 signaling proteins: MAPK, Rap1, NF-kappa B, HIF-1, PI3K-Akt, Wnt, TGF-beta, Hippo and TNF, which indicated the core neuro-inflammation signaling pathways responding to the low-level and weakly activated inflammation and hypoxia, and leading to the chronic neuro-degeneration. The core neuro-inflammation signaling pathways can be used as novel therapeutic targets for effective AD treatment and prevention.</p>
</abstract>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="intro">
<title>Introduction</title>
<p id="P2">A major challenge limiting effective treatments for Alzheimer’s disease (AD) is the complexity of AD. More than 42 genes/loci have been associated with AD<sup>
<xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R2">2</xref>
</sup>. Unfortunately, only few of these genes, like <italic>CD33</italic>
<sup>
<xref ref-type="bibr" rid="R3">3</xref>
</sup>, <italic>TREM2</italic>
<sup>
<xref ref-type="bibr" rid="R4">4</xref>
</sup>, <italic>MS4A</italic>
<sup>
<xref ref-type="bibr" rid="R5">5</xref>
</sup>, are being evaluated as therapeutic targets for AD management<sup>
<xref ref-type="bibr" rid="R1">1</xref>
</sup>. Over 240 drugs have been tested in AD clinical trials, but no new drugs have been approved for AD since 2003<sup>
<xref ref-type="bibr" rid="R6">6</xref>,<xref ref-type="bibr" rid="R7">7</xref>
</sup>. One major challenge is that the complicated pathogenesis and core signaling pathways of AD remains unclear. Therefore, it is significant to uncover the core signaling pathways implicated on AD pathogenesis and novel therapeutic targets of AD for identifying effective drugs and synergistic drug combinations (targeting multiple essential targets on the cores signaling network) for AD prevention or treatment.</p>
<p id="P3">Our knowledge of the molecular mechanisms and signaling pathways that ultimately lead to the chronic neurodegeneration in AD is limited. For example, there are only a few strong genetic biomarkers for AD that have been identified, including the <italic>APOE, APP, PSEN1/2</italic> genes. However, the signaling consequence of these biomarkers as they relate to the accumulation of dysfunctional A-beta and p-Tau proteins, as well as neuron death and immune response remain unclear. Over the last 10 years, neuro-inflammation and immune signaling have been being identified as the third core feature or a central pathogenesis mechanism of AD<sup>
<xref ref-type="bibr" rid="R8">8</xref>,<xref ref-type="bibr" rid="R9">9</xref>,<xref ref-type="bibr" rid="R10">10</xref>,<xref ref-type="bibr" rid="R11">11</xref>,<xref ref-type="bibr" rid="R12">12</xref>
</sup>, in addition to amyloid β plaques (Aβ) and neurofibrillary tangles (NFTs) pathologies. However, our knowledge of neuro-inflammation and immune signaling and their roles in neuro-degeneration is limited, though a set of inflammation and immune genes, like TNF, IL-1beta, IL-6, NFkB have been reported. No computational network analysis has been specifically designed and conducted to uncover and understand the neuro-inflammation and immune signaling pathways systematically. Therefore, it is important to continue to pursue systematic investigations, including the use of network analysis techniques, in order to uncover and understand the details of core signaling pathways, and the core neuroinflammation and immune signaling pathways that are associated the neurodegeneration of AD.</p>
<p id="P4">In response to the preceding gap in knowledge, we have systematically sought to identify the potential core signaling pathways causing neuron death and/or degeneration in AD by analyzing the RNA-seq data of human AD samples<sup>
<xref ref-type="bibr" rid="R13">13</xref>,<xref ref-type="bibr" rid="R14">14</xref>
</sup>. Instead of identifying the strongly activated molecular signals in the computational network analysis15, our unique contribution via this study is to identify the ‘weakly’ activated signaling pathways that may lead to neuron death in a chronic manner. The rationale of focusing on the weakly activated signaling pathways is that the only weakly activated signaling can cause the neuron death/degeneration in a chronic process. Whereas, strongly activated signaling pathways often cause acute disease progression, such as what is observed in a variety of cancers16,17 and COVID-1918,19. Specifically, we employed the RNA-seq data of neuropathology-free controls and AD samples from two datasets: ROSMAP<sup>
<xref ref-type="bibr" rid="R13">13</xref>,<xref ref-type="bibr" rid="R14">14</xref>
</sup> and Mayo Clinic20. Leveraging this data, we then identified all of the weakly activated and inhibited genes with very low fold change thresholds. Subsequently, we conducted network enrichment analyses to identify relevant core signaling pathways. Further, a network inference analysis was conducted to uncover the potential signaling cascades causing neuron death from the activated signaling pathways.</p>
</sec>
<sec id="S2" sec-type="results">
<title>Results</title>
<sec id="S3">
<title>Normal and AD tissue samples are barely separable in the gene expression data space</title>
<p id="P5">There were 77 normal control subjects and 81 AD cases in Mayo dataset; and 260 normal control samples and 97 AD cases in ROSMAP dataset. The transcripts per million (TPM) values of 16,132 protein coding genes were obtained by applying the Salmon quantification tool<sup>
<xref ref-type="bibr" rid="R21">21</xref>
</sup> in alignment-based mode using the STAR aligned RNA-seq data. A multidimensional scaling (MDS) model was used to generate the 2D clustering plots of normal control and AD samples in the Mayo and ROSMAP datasets respectively (see <xref ref-type="fig" rid="F1">Fig. 1</xref>). As is seen in these visualizations, the normal and AD samples are barely separable, especially in the ROSMAP dataset, which of note, has more normal samples than Mayo dataset.</p>
<p id="P6">We further conducted a widely used differential expression analysis method to identify differentially expressed genes (DEGs) between the AD and normal control samples. To identify the common set of DEGs between the two datasets, we applied a number of fold-change and p-value thresholds. As seen in <xref ref-type="table" rid="T1">Table 1</xref> and expected from <xref ref-type="fig" rid="F1">Fig. 1</xref>, only a few common up- and down-regulated DEGs were identified with fold change thresholds &gt;= 1.5 and p-value &lt;= 0.05. Even with the fold change threshold &gt;= 1.25, only about 230 up- and about 60 down-regulated genes were identified (out of the 16,132 protein coding genes, ~1.85%), in both studies. When relaxing both thresholds to fold change &gt;= 1.1 and p-value &lt;= 0.1, 1,120 up-regulated genes and 689 down-regulated genes were identified (~11.2% of the 161,32 protein-coding genes). Based upon these observations, we hypothesized that the AD-associated signaling pathways are weakly activated or inhibited.</p>
</sec>
<sec id="S4">
<title>Weak inflammation and hypoxia are the potential major factors in the AD brain microenvironment causing neuron cell death</title>
<p id="P7">As was noted previously, we believe it is important to identify AD-associated weakly activated signaling pathways, and understand their roles in AD disease progression, as well as their potential roles as targeted for AD therapeutics. Among the 1,120 common up-regulated genes (identified from Mayo and ROSMAP datasets), 417 genes were included in the 311 KEGG signaling pathways. To this end, we first conducted an enrichment analysis of KEGG signaling pathways using Fisher’s exact test applied to the 417 up-regulated genes. <xref ref-type="table" rid="T3">Table 2</xref> showed the enriched signaling pathways with p-value &lt;= 0.15. We then clustered these activated signaling pathway empirically into 7 categories (see <xref ref-type="fig" rid="F2">Fig. 2</xref>). Using these 417 up-regulated genes, the first principal component values in the MDS analysis of the AD and control samples were used to compared the difference in AD and control samples. The OR, absolute beta values and p-values of logistic regression analysis (see <xref ref-type="table" rid="T2">Table 2</xref>) indicated that these selected genes (p-value=1.22×10<sup>-13</sup> (Mayo) and p-value=4.2×10<sup>-6</sup> (ROSMAP)) can separate the AD and control samples much better than using all protein genes (p-value=0.036(Mayo) and p-value=0.027 (ROSMAP)) in the two datasets respectively. The bar-plots were also provided in <xref ref-type="fig" rid="F2">Fig. 2</xref>, which indicated that the control and AD samples are more separable using the selected genes.</p>
<p id="P8">As seen in our results (see <xref ref-type="fig" rid="F3">Fig.3</xref> and <xref ref-type="table" rid="T4">Table 3</xref>), a set of signaling pathways were activated, such as those involved in virus infection signaling (including: Epstein-Barr virus, Human T-cell leukemia virus 1 infection, Legionellosis, Pathogenic Escherichia coli infection, Staphylococcus aureus infection, Yersinia infection, Human cytomegalovirus infection, Human papillomavirus infection, Malaria, Human immunodeficiency virus 1 infection, Rheumatoid arthritis, and Inflammatory bowel disease [IBD]). There are 111 genes (out of the 417 up-regulated genes) in common across these pathways highlighting a set of core genes implicated on these processes. These results indicated that weakly activated inflammation related signaling pathways, like inflammation, cytokine, and immune response, may be represent activated signaling pathways in the AD brain microenvironment.</p>
<p id="P9">In addition, a group of activated signaling pathways or factors that are not clustering to a specific biological function or disease (referred to as the x-signaling pathway: the Hippo, PI3K-Akt, AGE-RAGE, MAPK, Adipocytokine, NF-kappa B, IL-17, TGF-beta, NOD-like receptor, TNF, Apoptosis, HIF-1 and Wnt signaling pathways, as well as apoptosis signaling) were identified. <xref ref-type="fig" rid="F4">Fig. 4</xref> shows the associations between these up-regulated genes and activated signaling pathways. As seen in <xref ref-type="fig" rid="F4">Fig. 4</xref>, a set of genes in the center areas of the network are associated with a set of signaling pathways, which could represent therapeutic signaling targets that could be used to inhibit or otherwise perturb these activated signaling pathways. In addition, there are a number of metabolisms signaling pathways, like Sulfur metabolism, Galactose metabolism, Starch and sucrose metabolism, Steroid hormone biosynthesis, Glycosaminoglycan degradation, implicated in this model. Moreover, Th1/2/17 (T helper, CD4+ cells) cell differentiation signaling was activated. Similarly, the natural killer cell mediated cytotoxicity signaling pathways were also activated. <xref ref-type="supplementary-material" rid="SD1">Table S1</xref> lists these associated up-regulated genes and the involved signaling pathways. All the observations suggest a potential novel hypothesis that the external inflammation, immune signaling and hypoxia signaling in AD microenvironment activated the <italic>MAPK, PI3K-Akt and mTOR</italic> signaling pathways, and then activated the <italic>HIF-1</italic> signaling pathway. However, the activation of <italic>HIF-1</italic> may fail to bring enough oxygen to protect against hypoxic injury to the involved neurons. The dysfunction of blood vessel functions, leading to hypoxia, might be partially indicated by the recent study showing that blood and cerebrospinal fluid flow cleaning the brain during sleeping<sup>
<xref ref-type="bibr" rid="R22">22</xref>
</sup>.</p>
</sec>
<sec id="S5">
<title>Weak inflammation and hypoxia are the major factors in the AD brain microenvironment causing neuron cell death</title>
<p id="P10">As was introduced above, many genes that are activated as a function of virus infection, immune response and the x-core signaling pathways are inflammation related genes. It is well known that virus infection and immune response signaling pathways respond to inflammation. Our analyses identified 1043 inflammation response genes in the gene ontology (GO) database (GO:0006954), that includes 492 genes in the KEGG signaling pathways. Interestingly, among the 417 up-regulated genes, 66 genes were inflammation related. The p-value of observing the 66 up-regulated inflammation signaling targets from 417 up-regulated genes identified in the AD vs = 1.77, which indicate that the activation of inflammation signaling is concomitant with AD progression. Furthermore, there are 66 overlapping up-regulated genes spanning the virus infection (from 111 up-regulated genes) and x-core signaling pathways (from 136 up-regulated genes), which indicate that the x-core signaling pathways are the likely pathways being activated in response to this inflammation. In addition, the activation of HIF-1 signaling pathway indicates the presence of hypoxia in the AD brain environment.</p>
<p id="P11">To further investigate the network signaling cascades involving inflammation and apoptosis genes, we conducted the network analysis incorporating the activated signaling pathways and apoptosis signaling genes. As seen in <xref ref-type="fig" rid="F5">Fig. 5</xref>, the potential signaling cascades linking the up-regulated inflammation related genes in virus infection and X-core signaling pathways to the activated apoptosis signaling targets. Among the 338 signaling network genes in <xref ref-type="fig" rid="F5">Fig. 5</xref>, there are 18 reported GWAS genes (with p-value &lt;= 1.0×10<sup>-5</sup>): <italic>PIK3CB, AKT3, RAF1, MAPK10, PPP2R2B, ERBB4, MECOM, IL1R1, MYD88, CAMK2D, GNB4, VAV3, PRKD3, PRKCE, THRB, FN1, LTBP1 WWTR1</italic>, which were reported in the GWAS analysis <sup>
<xref ref-type="bibr" rid="R26">26</xref>
</sup>. Further, we also compared the distance distribution among the inflammation related up-regulated genes and apoptosis genes as shown in <xref ref-type="fig" rid="F6">Fig. 6</xref>. As can be seen, the inflammation signaling genes are much closer, based on the shortest path metric calculated using the Dijkstra’s algorithm, on the signaling network, (see green, blue and red nodes) to the apoptosis genes compared with other signaling genes (see gray lines). These results indicate a potential signaling interactions between the inflammation signaling genes and apoptosis signaling. In other words, the results suggest a potential association that the weak inflammation and hypoxia signaling in the AD brain environment led to chronic neurodegeneration process via the activation of the x-core signaling pathways. Therefore, drugs and drug combinations that can perturb the X-core signaling pathways have the potential to be effective for AD prevention and treatment.</p>
</sec>
<sec id="S6">
<title>Activated TNF signaling might lead the programmed apoptosis of neurons</title>
<p id="P12">Of note, our results show that among the X-core signaling pathways, the TNF signaling pathways are also activated. Particularly, the TNF (Tumor Necrosis Factor) receptors (TNFRSF1A TNFRSF10A, and TNFRSF10B) were up-regulated (see <xref ref-type="table" rid="T5">Table 4</xref>). We reconstructed these signaling pathway linking the TNF receptors to the up-regulated genes in TNF and apoptosis signaling pathways (see in <xref ref-type="fig" rid="F7">Fig. 7</xref>). As seen, the activation of these TNF signaling pathway might be one possible molecular mechanism causing the activation of apoptosis signaling via the CASP6, CASP7 cascades.</p>
</sec>
<sec id="S7">
<title>Circadian entrainment, addiction, Neuroactive Neuroactive ligand-receptor, Synaptic vesicle cycle, Fat acid biosynthesis, mTOR and oxidative phosphorylation signaling pathways were down-regulated inhibited in AD tissues</title>
<p id="P13">We also conducted pathway enrichment analyses using 143 down-regulated genes in KEGG signaling pathways. There are far fewer down-regulated genes and lower inhibition down-regulated of KEGG signaling pathways, compared with up-regulated genes (see <xref ref-type="table" rid="T6">Table 5</xref>). As shown in <xref ref-type="fig" rid="F8">Fig. 8</xref>, the circadian entrainment, addition, Neuroactive neuroactive ligand-receptor, Synaptic vesicle cycle, Fat acid biosynthesis and oxidative phosphorylation genes pathways were inhibited in AD, which is associated with the down-regulated Ras and cAMP signaling pathways.</p>
<p id="P14">The dysfunctional circadian entrainment signaling pathway were reported to be associated with AD, and might be associated with the rhythmic spinal fluid washing over brain during deep sleep. In addition, the mTOR signaling and oxidative phosphorylation signaling pathways were down-regulated. Moreover, fat acid biosynthesis and elongation were also inhibited.</p>
</sec>
</sec>
<sec id="S8" sec-type="methods">
<title>Methods</title>
<sec id="S9">
<title>Gene expression data analysis of Apoe4/4 genotype AD samples</title>
<p id="P15">In this study, 77 normal tissue samples and 81 AD tissue samples in Mayo dataset; and 97 normal samples and 260 AD samples in ROSMAP dataset were used. Both datasets were processed and aligned separately using reference genome GRCh38 and GENCODE 33 annotation including the ERCC spike-in annotations. We excluded ALT, HLA, and Decoy contigs from the reference genome due to the lack of RNA-Seq tools that allow to handle these regions properly. To obtain gene expression data, all read sequences from both datasets were first mapped to the reference genome using STAR (v.2.7.1a)<sup>
<xref ref-type="bibr" rid="R23">23</xref>
</sup>. Transcripts per million (TPM) values of 16,132 common protein coding genes were then obtained in the two datasets by applying the Salmon quantification tool21 in alignment-based mode using the aligned RNA-seq data.</p>
</sec>
<sec id="S10">
<title>Differentially expressed genes</title>
<p id="P16">To identify the up- and down-regulated genes in AD samples vs normal control samples, the edgeR<sup>
<xref ref-type="bibr" rid="R24">24</xref>
</sup> tool, using the negative binomial (NB) statistical model, was applied to the TPM values.</p>
</sec>
<sec id="S11">
<title>Inflammation genes</title>
<p id="P17">A set of inflammation genes were obtained by extracting genes from the inflammatory response category as defined in the Gene Ontology (GO:0006954)<sup>
<xref ref-type="bibr" rid="R25">25</xref>
</sup>. Subsequently, 485 inflammation genes were obtained from the 5,191 KEGG signaling genes.</p>
</sec>
<sec id="S12">
<title>AD GWAS data</title>
<p id="P18">The GWAS data of AD was obtained from niagads database<sup>
<xref ref-type="bibr" rid="R26">26</xref>
</sup> (<ext-link ext-link-type="uri" xlink:href="https://www.niagads.org/igap-rv-summary-stats-kunkle-p-value-data">https://www.niagads.org/igap-rv-summary-stats-kunkle-p-value-data</ext-link>). The Stage 1 P-Value Data (updated by February 26, 2019) and Stage 2 P-Value Data (updated by February 27, 2019) were downloaded. The 553 candidate GWAS genes and also available in the KEGG signaling pathways were obtained by a filter with p-value &lt;= 1.0×10<sup>-5</sup>.</p>
</sec>
<sec id="S13">
<title>KEGG signaling pathway enrichment analysis</title>
<p id="P19">The KEGG signaling pathways consist of 311 signaling pathways27,28. There are 59,242 signaling interaction among 5,191 genes in these pathways, which were used for network enrichment analysis and network inference analysis in this study. For the network enrichment analysis, a Fisher’s exact test29,30 was used based upon the up-regulated genes.</p>
</sec>
<sec id="S14">
<title>KEGG signaling network inference analysis</title>
<p id="P20">To infer the signaling cascades among a set of genes of interest, we developed a network inference approach. First, we divided the genes into two groups: signaling sources (like the inflammation signaling genes), and signaling targets (like the apoptosis signaling genes). Second, a signaling network was constructed by linking the signaling source genes to the signaling target genes iteratively. Specifically, the signaling source genes was used as the initial signaling source nodes set: V0. The signaling target genes were used as the target nodes set: V1. In the iterative process, the shortest signaling cascades/paths between the nodes in V0 and V1 were calculated and identified: <italic>P<sub>ij</sub> = &lt;g<sub>i</sub>, g<sub>k1</sub>, g<sub>k2</sub>, …, g<sub>j</sub>&gt;, where g<sub>i</sub> belongs to V0, and g<sub>j</sub> belongs to V1.</italic> Third, all of the genes on the signaling path <italic>P<sub>ij</sub>
</italic> and belong to V1 were selected and added to V0, and removed from V1. This process was repeated until all the genes were added to V0.</p>
</sec>
</sec>
<sec id="S15" sec-type="discussion | conclusions">
<title>Discussion and conclusion</title>
<p id="P21">Neuro-inflammation and immune signaling have been being identified as an important pathogenesis mechanism of AD, in addition to amyloid β plaques (Aβ) and neurofibrillary tangles (NFTs) pathologies. However, our knowledge of neuro-inflammation and immune signaling and their roles in neuro-degeneration is limited, though a set of inflammation and immune genes, like TNF, IL-1beta, IL-6, NFkB have been reported. Recently, the network analysis models were proposed to identify the potential dysfunctional signaling pathways and biomarkers using the related RNA-seq datasets. For example, the molecular signatures and networks under different brain regions were reported using integrative co-expression network analysis, and the myelin signaling dysregulation was identified in AD<sup>
<xref ref-type="bibr" rid="R31">31</xref>,<xref ref-type="bibr" rid="R32">32</xref>
</sup>. In addition, the co-splicing network using the WGCNA (co-expression network analysis model) was conducted to identified the altered splicing in AD, which indicated that the altered splicing is the mechanism for the effects of the AD related CLU, PTK2b and PICALM alleles33. Moreover, the molecular subtypes and potential driver genes, like CABRB2, LRP10, ATP6V1A, of AD were identified by combing key driver analysis (KDA) and multiscale embedded gene expression network analysis (MEGENA)34,35,36. However, neuro-inflammation and immune signaling pathways have not been systematically uncovered and analyzed in these reported computational models. Compared with these reported studies, our unique contribution is the novel discovery of essential neuro-inflammation and immune signaling genes and signaling interactions using systematic network analysis models, which indicates potentially novel targets and mechanisms of neuro-inflammation and immune signaling in neuro-degeneration.</p>
<p id="P22">Specifically, we propose a novel hypothesis that weakly activated neuro-inflammation signaling pathways can cause neuro-degeneration in a chronic process; whereas, strongly activated neuro-inflammation often cause acute disease progression like in COVID-19. Consequently, from a novel perspective, i.e., investigating the weakly activated molecular signals (rather than the strongly activated molecular signals), in this study, we uncovered the core neuro-inflammation signaling pathways in AD. To the best of our knowledge, it is the first time to systematically uncover the core neuro-inflammation signaling pathways based on the transcriptomic data of AD. The neuro-inflammation signaling pathways, including the virus infection, immune response, x-core signaling pathways, apoptosis signaling pathways. indicated that such weak inflammation may lead to the activation of x-core signaling pathways and the ultimate apoptosis of neurons. As a result, we hypothesize that drugs and drug combination inhibiting the neuro-inflammation signaling pathways could be potentially effective for AD prevention and treatment. Moreover, it is interesting to investigate the detailed signaling cascades of the x-core signaling pathways, including the MAPK, Rap1, NF-kappa B, HIF-1, PI3K-Akt, Wnt, TGF-beta, Hippo and TNF signaling pathways. And it is important to study their roles in Aβ plaques and tau tangles as well as neuro-degeneration.</p>
</sec>
<sec sec-type="supplementary-material" id="SM">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<label>Supplementary Material</label>
<media xlink:href="EMS134243-supplement-Supplementary_Material.pdf" mimetype="application" mime-subtype="pdf" id="N66274" position="anchor"/>
</supplementary-material>
</sec>
</body>
<back>
<ack id="S16">
<title>Acknowledgement</title>
<p>This work is partially supported by National Institute of Ageing (NIA) R56AG065352 to Dr. Li. We thank all the participants and their families, as well as the many involved institutions and their staff. Funding: This work was supported by grants from the National Institutes of Health (R01AG044546 (CC), P01AG003991(CC, JCM), RF1AG053303 (CC), RF1AG058501 (CC), and U01AG058922 (CC), and chuck zuckerberg initiative (CZI). This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, and the Departments of Neurology and Psychiatry at Washington University School of Medicine. CC receives research support from: Biogen, EISAI, Alector and Parabon. CC is a member of the advisory board of Vivid Genomics, Halia Therapeutics and ADx Healthcare. The remaining authors declare no competing interests.</p>
</ack>
<ref-list>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verheijen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sleegers</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Understanding Alzheimer Disease at the Interface between Genetics and Transcriptomics</article-title>
<source>Trends in Genetics</source>
<year>2018</year>
<volume>34</volume>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sims</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>
<article-title>Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer’s disease</article-title>
<source>Nature Genetics</source>
<year>2017</year>
<volume>49</volume>
<fpage>1373</fpage>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>CD33 in Alzheimer’s Disease – Biology, Pathogenesis, and Therapeutics: A Mini-Review</article-title>
<source>Gerontology</source>
<year>2019</year>
<volume>65</volume>
<fpage>323</fpage>
<lpage>331</lpage>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gratuze</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Leyns</surname>
<given-names>CEG</given-names>
</name>
<name>
<surname>Holtzman</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>New insights into the role of TREM2 in Alzheimer’s disease</article-title>
<source>Molecular Neurodegeneration</source>
<year>2018</year>
<volume>13</volume>
<fpage>66</fpage>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deming</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>The &lt;em&gt;MS4A&lt;/em&gt; gene cluster is a key modulator of soluble TREM2 and Alzheimer’s disease risk</article-title>
<source>Science Translational Medicine</source>
<year>2019</year>
<volume>11</volume>
<elocation-id>eaau2291</elocation-id>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<article-title>2018 Alzheimer’s disease facts and figures</article-title>
<source>Alzheimer’s &amp; Dementia</source>
<year>2018</year>
<volume>14</volume>
<fpage>367</fpage>
<lpage>429</lpage>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cummings</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ritter</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Alzheimer’s disease drug development pipeline: 2018</article-title>
<source>Alzheimer’s and Dementia: Translational Research and Clinical Interventions</source>
<year>2018</year>
<volume>4</volume>
<fpage>195</fpage>
<lpage>214</lpage>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kinney</surname>
<given-names>JW</given-names>
</name>
<etal/>
</person-group>
<article-title>Inflammation as a central mechanism in Alzheimer’s disease</article-title>
<source>Alzheimer’s &amp; dementia (New York, N. Y.)</source>
<year>2018</year>
<volume>4</volume>
<fpage>575</fpage>
<lpage>590</lpage>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Newcombe</surname>
<given-names>EA</given-names>
</name>
<etal/>
</person-group>
<article-title>Inflammation: the link between comorbidities, genetics, and Alzheimer’s disease</article-title>
<source>Journal of Neuroinflammation</source>
<year>2018</year>
<volume>15</volume>
<fpage>276</fpage>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akiyama</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>
<article-title>Inflammation and Alzheimer’s disease</article-title>
<source>Neurobiology of aging</source>
<year>2000</year>
<volume>21</volume>
<fpage>383</fpage>
<lpage>421</lpage>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Combs</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Karlo</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Cannady</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Landreth</surname>
<given-names>GE</given-names>
</name>
</person-group>
<article-title>Inflammatory mechanisms in Alzheimer’s disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists</article-title>
<source>The Journal of neuroscience : the official journal of the Society for Neuroscience</source>
<year>2000</year>
<volume>20</volume>
<fpage>558</fpage>
<lpage>567</lpage>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knezevic</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Mizrahi</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Molecular imaging of neuroinflammation in Alzheimer’s disease and mild cognitive impairment</article-title>
<source>Progress in neuro-psychopharmacology &amp; biological psychiatry</source>
<year>2018</year>
<volume>80</volume>
<fpage>123</fpage>
<lpage>131</lpage>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Jager</surname>
<given-names>PL</given-names>
</name>
<etal/>
</person-group>
<article-title>A multi-omic atlas of the human frontal cortex for aging and Alzheimer’s disease research</article-title>
<source>Scientific data</source>
<year>2018</year>
<volume>5</volume>
<elocation-id>180142</elocation-id>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bennett</surname>
<given-names>DA</given-names>
</name>
<etal/>
</person-group>
<article-title>Religious Orders Study and Rush Memory and Aging Project</article-title>
<source>Journal of Alzheimer’s disease : JAD</source>
<year>2018</year>
<volume>64</volume>
<fpage>S161</fpage>
<lpage>S189</lpage>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neff</surname>
<given-names>RA</given-names>
</name>
<etal/>
</person-group>
<article-title>Molecular subtyping of Alzheimer{\textquoteright}s disease using RNA sequencing data reveals novel mechanisms and targets</article-title>
<source>Science Advances</source>
<year>2021</year>
<volume>7</volume>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanchez-Vega</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>
<article-title>Oncogenic Signaling Pathways in The Cancer Genome Atlas</article-title>
<source>Cell</source>
<year>2018</year>
<volume>173</volume>
<fpage>321</fpage>
<lpage>337</lpage>
<elocation-id>e10</elocation-id>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Investigating the relevance of major signaling pathways in cancer survival using a biologically meaningful deep learning model</article-title>
<source>BMC Bioinformatics</source>
<year>2021</year>
<volume>22</volume>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gordon</surname>
<given-names>DE</given-names>
</name>
<etal/>
</person-group>
<article-title>A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing</article-title>
<source>bioRxiv</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1101/2020.03.22.002386</pub-id>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fuhai</surname>
<given-names>Li</given-names>
</name>
<name>
<surname>Andrew</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Michelson</surname>
<given-names>RandiForaker</given-names>
</name>
<name>
<surname>Ming Zhan</surname>
<given-names>PROP</given-names>
</name>
</person-group>
<source>Repurposing drugs for COVID-19 based on transcriptional response of host cells to SARS-CoV-2</source>
<year>2020</year>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://arxiv.org/abs/2006.01226">https://arxiv.org/abs/2006.01226</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Allen</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Human whole genome genotype and transcriptome data for Alzheimer’s and other neurodegenerative diseases</article-title>
<source>Scientific data</source>
<year>2016</year>
<volume>3</volume>
<elocation-id>160089</elocation-id>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patro</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Duggal</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Love</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Irizarry</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Kingsford</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Salmon provides fast and bias-aware quantification of transcript expression</article-title>
<source>Nature methods</source>
<year>2017</year>
<volume>14</volume>
<fpage>417</fpage>
<lpage>419</lpage>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fultz</surname>
<given-names>NE</given-names>
</name>
<etal/>
</person-group>
<article-title>Coupled electrophysiological, hemodynamic, and cerebrospinal fluid oscillations in human sleep</article-title>
<source>Science</source>
<year>2019</year>
<volume>366</volume>
<fpage>628</fpage>
<lpage>631</lpage>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dobin</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>STAR: ultrafast universal RNA-seq aligner</article-title>
<source>Bioinformatics (Oxford, England)</source>
<year>2013</year>
<volume>29</volume>
<fpage>15</fpage>
<lpage>21</lpage>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robinson</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>McCarthy</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Smyth</surname>
<given-names>GK</given-names>
</name>
</person-group>
<article-title>edgeR: a Bioconductor package for differential expression analysis of digital gene expression data</article-title>
<source>Bioinformatics (Oxford, England)</source>
<year>2010</year>
<volume>26</volume>
<fpage>139</fpage>
<lpage>140</lpage>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<collab>Gene Ontology Consortium, T</collab>
<article-title>Gene Ontology: tool for the unification of biology NIH Public Access Author Manuscript</article-title>
<source>Nat Genet</source>
<year>2000</year>
<volume>25</volume>
<fpage>25</fpage>
<lpage>29</lpage>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kunkle</surname>
<given-names>BW</given-names>
</name>
<etal/>
</person-group>
<article-title>Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing</article-title>
<source>Nature Genetics</source>
<year>2019</year>
<volume>51</volume>
<fpage>414</fpage>
<lpage>430</lpage>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ogata</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>
<article-title>KEGG: Kyoto encyclopedia of genes and genomes</article-title>
<source>Nucleic Acids Research</source>
<year>1999</year>
<volume>28</volume>
<pub-id pub-id-type="doi">10.1093/nar/27.1.29</pub-id>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanehisa</surname>
<given-names>MGS</given-names>
</name>
<name>
<surname>Goto</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>KEGG: kyoto Encyclopedia of Genes and Genomes</article-title>
<source>Nucleic acids research</source>
<year>2000</year>
<volume>28</volume>
<fpage>27</fpage>
<lpage>30</lpage>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fisher</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Statistical methods for research workers</article-title>
<source>Oliver and Boyd</source>
<year>1932</year>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>H-Y</given-names>
</name>
</person-group>
<article-title>Statistical notes for clinical researchers: Chi-squared test and Fisher’s exact test</article-title>
<source>Restorative dentistry &amp; endodontics</source>
<year>2017</year>
<volume>42</volume>
<fpage>152</fpage>
<lpage>155</lpage>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Integrative network analysis of nineteen brain regions identifies molecular signatures and networks underlying selective regional vulnerability to Alzheimer’s disease</article-title>
<source>Genome Medicine</source>
<year>2016</year>
<volume>8</volume>
<fpage>104</fpage>
</element-citation>
</ref>
<ref id="R32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wan</surname>
<given-names>Y-W</given-names>
</name>
<etal/>
</person-group>
<article-title>Meta-Analysis of the Alzheimer’s Disease Human Brain Transcriptome and Functional Dissection in Mouse Models</article-title>
<source>Cell Reports</source>
<year>2020</year>
<volume>32</volume>
<elocation-id>107908</elocation-id>
</element-citation>
</ref>
<ref id="R33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raj</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>
<article-title>Integrative transcriptome analyses of the aging brain implicate altered splicing in Alzheimer’s disease susceptibility</article-title>
<source>Nature Genetics</source>
<year>2018</year>
<volume>50</volume>
<fpage>1584</fpage>
<lpage>1592</lpage>
</element-citation>
</ref>
<ref id="R34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McKenzie</surname>
<given-names>AT</given-names>
</name>
<etal/>
</person-group>
<article-title>Multiscale network modeling of oligodendrocytes reveals molecular components of myelin dysregulation in Alzheimer’s disease</article-title>
<source>Molecular Neurodegeneration</source>
<year>2017</year>
<volume>12</volume>
<fpage>82</fpage>
</element-citation>
</ref>
<ref id="R35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neff</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Vatansever</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Transformative Network Modeling of Multi-omics Data Reveals Detailed Circuits, Key Regulators, and Potential Therapeutics for Alzheimer’s Disease</article-title>
<source>Neuron</source>
<year>2020</year>
<volume>109</volume>
</element-citation>
</ref>
<ref id="R36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neff</surname>
<given-names>RA</given-names>
</name>
<etal/>
</person-group>
<article-title>Molecular subtyping of Alzheimer’s disease using RNA sequencing data reveals novel mechanisms and targets</article-title>
<source>Science advances</source>
<year>2021</year>
<volume>7</volume>
<elocation-id>eabb5398</elocation-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>AD and normal control tissue samples are not well separable using an MDS plot on the RNA-seq protein-coding genes in Mayo (<bold>top-panel</bold>) and ROSMAP (<bold>bottom-panel</bold>) datasets.</p>
</caption>
<graphic xlink:href="EMS134243-f001"/>
</fig>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>Box-plots of the first principal component of MDS analysis in control and AD cases. <bold>Left and right columns</bold> are Mayo and RosMap samples respectively. <bold>Upper and lower panels</bold> represent the MDS analysis using all genes and 417 up-regulated genes respectively.</p>
</caption>
<graphic xlink:href="EMS134243-f002"/>
</fig>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<title>Seven categories of weakly activated signaling pathways in AD.</title>
</caption>
<graphic xlink:href="EMS134243-f003"/>
</fig>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption>
<title>The up-regulated gene-pathway interaction network, including 1021 interactions between 291 up-regulated genes and 61 enriched pathways.</title>
</caption>
<graphic xlink:href="EMS134243-f004"/>
</fig>
<fig id="F5" position="float">
<label>Figure 5</label>
<caption>
<p>Signaling cascades linking the up-regulated signaling genes in the virus infection pathways (cyan) (<bold>top</bold>) and x-core signaling pathways (<bold>bottom</bold>) to the up-regulated apoptosis signaling genes (red) via the linking genes (pink).</p>
</caption>
<graphic xlink:href="EMS134243-f005"/>
</fig>
<fig id="F6" position="float">
<label>Figure 6</label>
<caption>
<p>The up-regulated genes in the inflammation related signaling pathways, including virus infection, immune response and x-core signaling pathways. As seen, the inflammation signaling genes are much closer (see green, blue and red) to the apoptosis genes compared with other signaling genes (see gray lines).</p>
</caption>
<graphic xlink:href="EMS134243-f006"/>
</fig>
<fig id="F7" position="float">
<label>Figure 7</label>
<caption>
<title>Signaling cascades, causing neuron death, from the 3 TNF receptors (cyan) to the up-regulated genes (red) in TNF and apoptosis signaling pathways via the linking genes (pink).</title>
</caption>
<graphic xlink:href="EMS134243-f007"/>
</fig>
<fig id="F8" position="float">
<label>Figure 8</label>
<caption>
<title>The down-regulated gene-pathway interaction network, including 183 interactions between 73 up-regulated genes and 30 enriched pathways.</title>
</caption>
<graphic xlink:href="EMS134243-f008"/>
</fig>
<table-wrap id="T1" position="float" orientation="portrait">
<label>Table 1</label>
<caption>
<title>Epidemiology information of Mayo and RosMap datasets.</title>
</caption>
<table frame="box" rules="all">
<thead>
<tr>
<th align="left" valign="top">Mayo</th>
<th align="center" valign="top">Control</th>
<th align="left" valign="top">AD</th>
<th align="left" valign="top"/>
<th align="left" valign="top">RosMap</th>
<th align="left" valign="top">Control</th>
<th align="left" valign="top">AD</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">In Total</td>
<td align="left" valign="top">77</td>
<td align="left" valign="top">81</td>
<td align="left" valign="top"/>
<td align="left" valign="top">In Total</td>
<td align="left" valign="top">97</td>
<td align="left" valign="top">260</td>
</tr>
<tr>
<td align="left" valign="top">Male</td>
<td align="left" valign="top">40</td>
<td align="left" valign="top">33</td>
<td align="left" valign="top"/>
<td align="left" valign="top">Male</td>
<td align="left" valign="top">44</td>
<td align="left" valign="top">82</td>
</tr>
<tr>
<td align="left" valign="top">Female</td>
<td align="left" valign="top">37</td>
<td align="left" valign="top">48</td>
<td align="left" valign="top"/>
<td align="left" valign="top">Female</td>
<td align="left" valign="top">53</td>
<td align="left" valign="top">178</td>
</tr>
<tr>
<td align="left" valign="top">Age Mean (SD)</td>
<td align="left" valign="top">82.65 (8.70)</td>
<td align="left" valign="top">82.57 (7.62)</td>
<td align="left" valign="top"/>
<td align="left" valign="top">Age Mean (SD)</td>
<td align="left" valign="top">84.24 (6.82)</td>
<td align="left" valign="top">90.34 (5.75)</td>
</tr>
<tr>
<td align="left" valign="top">APOE_22</td>
<td align="left" valign="top">0</td>
<td align="left" valign="top">0</td>
<td align="left" valign="top"/>
<td align="left" valign="top">APOE_22</td>
<td align="left" valign="top">2</td>
<td align="left" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top">APOE_23</td>
<td align="left" valign="top">12</td>
<td align="left" valign="top">4</td>
<td align="left" valign="top"/>
<td align="left" valign="top">APOE_23</td>
<td align="left" valign="top">13</td>
<td align="left" valign="top">22</td>
</tr>
<tr>
<td align="left" valign="top">APOE_33</td>
<td align="left" valign="top">56</td>
<td align="left" valign="top">34</td>
<td align="left" valign="top"/>
<td align="left" valign="top">APOE_33</td>
<td align="left" valign="top">72</td>
<td align="left" valign="top">141</td>
</tr>
<tr>
<td align="left" valign="top">APOE_24</td>
<td align="left" valign="top">1</td>
<td align="left" valign="top">0</td>
<td align="left" valign="top"/>
<td align="left" valign="top">APOE_24</td>
<td align="left" valign="top">1</td>
<td align="left" valign="top">10</td>
</tr>
<tr>
<td align="left" valign="top">APOE_34</td>
<td align="left" valign="top">8</td>
<td align="left" valign="top">36</td>
<td align="left" valign="top"/>
<td align="left" valign="top">APOE_34</td>
<td align="left" valign="top">8</td>
<td align="left" valign="top">83</td>
</tr>
<tr>
<td align="left" valign="top">APOE_44</td>
<td align="left" valign="top">0</td>
<td align="left" valign="top">7</td>
<td align="left" valign="top"/>
<td align="left" valign="top">APOE_44</td>
<td align="left" valign="top">1</td>
<td align="left" valign="top">3</td>
<td align="left" valign="top"/>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T2" position="float" orientation="portrait">
<label>Table 1</label>
<caption>
<title>Differentially expressed genes (DEGs) out of 16,132 common protein coding genes between AD and control samples in Mayo and ROSMAP datasets.</title>
</caption>
<table frame="box" rules="all">
<thead>
<tr>
<th align="center" valign="top">Fold<break/>change</th>
<th align="center" valign="top">P-value</th>
<th align="center" valign="top"># of DEGs<break/>in Mayo</th>
<th align="center" valign="top"># of DEGs<break/>in ROSMAP</th>
<th align="center" valign="top"># of Common DEGs<break/>in Mayo and<break/>ROSMAP</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" valign="top">&gt;=2.0</td>
<td align="center" valign="top">&lt;=0.05</td>
<td align="center" valign="top">22 (up), 5 (down)</td>
<td align="center" valign="top">0 (up), 0 (down)</td>
<td align="center" valign="top">0 (up), 0 (down)</td>
</tr>
<tr>
<td align="center" valign="top">&gt;=2.0</td>
<td align="center" valign="top">&lt;=0.1</td>
<td align="center" valign="top">22 (up), 5 (down)</td>
<td align="center" valign="top">0 (up), 0 (down)</td>
<td align="center" valign="top">0 (up), 0 (down)</td>
</tr>
<tr>
<td align="center" valign="top">&gt;=1.5</td>
<td align="center" valign="top">&lt;=0.05</td>
<td align="center" valign="top">210 (up), 84 (down)</td>
<td align="center" valign="top">30 (up), 5 (down)</td>
<td align="center" valign="top">15 (up), 4 (down)</td>
</tr>
<tr>
<td align="center" valign="top">&gt;=1.5</td>
<td align="center" valign="top">&lt;=0.1</td>
<td align="center" valign="top">210 (up), 86 (down)</td>
<td align="center" valign="top">30 (up), 5 (down)</td>
<td align="center" valign="top">15 (up), 4 (down)</td>
</tr>
<tr>
<td align="center" valign="top">&gt;=1.25</td>
<td align="center" valign="top">&lt;=0.05</td>
<td align="center" valign="top">958 (up), 873 (down)</td>
<td align="center" valign="top">487 (up), 123 (down)</td>
<td align="center" valign="top">227 (up), 56 (down)</td>
</tr>
<tr>
<td align="center" valign="top">&gt;=1.25</td>
<td align="center" valign="top">&lt;=0.1</td>
<td align="center" valign="top">962 (up), 883 (down)</td>
<td align="center" valign="top">488 (up), 126 (down)</td>
<td align="center" valign="top">230 (up), 64 (down)</td>
</tr>
<tr>
<td align="center" valign="top">&gt;=1.1</td>
<td align="center" valign="top">&lt;=0.05</td>
<td align="center" valign="top">2457 (up), 3687 (down)</td>
<td align="center" valign="top">2610 (up), 1752 (down)</td>
<td align="center" valign="top">1009 (up), 604 (down)</td>
</tr>
<tr>
<td align="center" valign="top">&gt;=1.1</td>
<td align="center" valign="top">&lt;=0.1</td>
<td align="center" valign="top">2609 (up), 3952 (down)</td>
<td align="center" valign="top">2700 (up), 1783 (down)</td>
<td align="center" valign="top">1120 (up), 689 (down)</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T3" position="float" orientation="portrait">
<label>Table 2</label>
<caption>
<title>Odds ratio (OR), beta and p-values of logistic regression using all gene and 417 up-regulated genes.</title>
</caption>
<table frame="box" rules="all">
<thead>
<tr>
<th align="center" valign="top"/>
<th align="center" valign="top" colspan="3">All genes</th>
<th align="center" valign="top" colspan="3">417 genes</th>
</tr>
<tr>
<td align="center" valign="top"/>
<th align="center" valign="top">OR</th>
<th align="center" valign="top">abs(beta)</th>
<th align="center" valign="top">p-value</th>
<th align="center" valign="top">OR</th>
<th align="center" valign="top">abs(beta)</th>
<th align="center" valign="top">p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" valign="top">
<bold>Mayo</bold>
</td>
<td align="center" valign="top">1.42</td>
<td align="center" valign="top">0.35</td>
<td align="center" valign="top">0.037</td>
<td align="center" valign="top">5.9</td>
<td align="center" valign="top">1.78</td>
<td align="center" valign="top">9.5×10<sup>-9</sup>
</td>
</tr>
<tr>
<td align="center" valign="top">
<bold>RosMap</bold>
</td>
<td align="center" valign="top">1.31</td>
<td align="center" valign="top">0.27</td>
<td align="center" valign="top">0.027</td>
<td align="center" valign="top">1.9</td>
<td align="center" valign="top">0.63</td>
<td align="center" valign="top">9.7*10<sup>-5</sup>
</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T4" position="float" orientation="portrait">
<label>Table 3</label>
<caption>
<title>The seven categories of enriched KEGG signaling pathways.</title>
</caption>
<table frame="box" rules="all">
<thead>
<tr>
<th align="left" valign="top">Name</th>
<th align="left" valign="top">p-value</th>
<th align="left" valign="top">Name</th>
<th align="left" valign="top">p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">
<bold>Virus related signaling pathways</bold>
</td>
<td align="left" valign="top"/>
<td align="left" valign="top">
<bold>X-core signaling pathways</bold>
</td>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">Viral protein interaction with cytokine and cytokine receptor</td>
<td align="left" valign="top">0.0019</td>
<td align="left" valign="top">PI3K-Akt signaling pathway</td>
<td align="left" valign="top">0.0011</td>
</tr>
<tr>
<td align="left" valign="top">Epstein-Barr virus infection</td>
<td align="left" valign="top">0.0056</td>
<td align="left" valign="top">MAPK signaling pathway</td>
<td align="left" valign="top">0.0059</td>
</tr>
<tr>
<td align="left" valign="top">Human T-cell leukemia virus 1 infection</td>
<td align="left" valign="top">0.0188</td>
<td align="left" valign="top">NF-kappa B signaling pathway</td>
<td align="left" valign="top">0.0085</td>
</tr>
<tr>
<td align="left" valign="top">Staphylococcus aureus infection</td>
<td align="left" valign="top">0.0249</td>
<td align="left" valign="top">Hippo signaling pathway</td>
<td align="left" valign="top">0.0132</td>
</tr>
<tr>
<td align="left" valign="top">Human papillomavirus infection</td>
<td align="left" valign="top">0.0299</td>
<td align="left" valign="top">TGF-beta signaling pathway</td>
<td align="left" valign="top">0.0137</td>
</tr>
<tr>
<td align="left" valign="top">Pertussis</td>
<td align="left" valign="top">0.0375</td>
<td align="left" valign="top">TNF signaling pathway</td>
<td align="left" valign="top">0.0434</td>
</tr>
<tr>
<td align="left" valign="top">Yersinia infection</td>
<td align="left" valign="top">0.0397</td>
<td align="left" valign="top">Rap1 signaling pathway</td>
<td align="left" valign="top">0.0571</td>
</tr>
<tr>
<td align="left" valign="top">Pathogenic Escherichia coli infection</td>
<td align="left" valign="top">0.0430</td>
<td align="left" valign="top">HIF-1 signaling pathway</td>
<td align="left" valign="top">0.1009</td>
</tr>
<tr>
<td align="left" valign="top">Human cytomegalovirus infection</td>
<td align="left" valign="top">0.0603</td>
<td align="left" valign="top">Wnt signaling pathway</td>
<td align="left" valign="top">0.1043</td>
</tr>
<tr>
<td align="left" valign="top">Malaria</td>
<td align="left" valign="top">0.0758</td>
<td align="left" valign="top">Apoptosis</td>
<td align="left" valign="top">0.0658</td>
</tr>
<tr>
<td align="left" valign="top">Legionellosis</td>
<td align="left" valign="top">0.0906</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">Human immunodeficiency virus 1 infection</td>
<td align="left" valign="top">0.1075</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">Rheumatoid arthritis</td>
<td align="left" valign="top">0.1192</td>
<td align="left" valign="top">
<bold>Mineral absorption</bold>
</td>
<td align="left" valign="top">2.56E-05</td>
</tr>
<tr>
<td align="left" valign="top">Inflammatory bowel disease (IBD)</td>
<td align="left" valign="top">0.1321</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">
<bold>Immune signaling pathways</bold>
</td>
<td align="left" valign="top"/>
<td align="left" valign="top">
<bold>Diabetic/Lipid signaling pathways</bold>
</td>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">IL-17 signaling pathway</td>
<td align="left" valign="top">0.0104</td>
<td align="left" valign="top">AGE-RAGE signaling pathway in diabetic complications</td>
<td align="left" valign="top">0.0021</td>
</tr>
<tr>
<td align="left" valign="top">Complement and coagulation cascades</td>
<td align="left" valign="top">0.0214</td>
<td align="left" valign="top">Adipocytokine signaling pathway</td>
<td align="left" valign="top">0.0060</td>
</tr>
<tr>
<td align="left" valign="top">NOD-like receptor signaling pathway</td>
<td align="left" valign="top">0.0401</td>
<td align="left" valign="top">Insulin resistance</td>
<td align="left" valign="top">0.0283</td>
</tr>
<tr>
<td align="left" valign="top">Th17 cell differentiation</td>
<td align="left" valign="top">0.1275</td>
<td align="left" valign="top">Glucagon signaling pathway</td>
<td align="left" valign="top">0.1179</td>
</tr>
<tr>
<td align="left" valign="top">Th1 and Th2 cell differentiation</td>
<td align="left" valign="top">0.1368</td>
<td align="left" valign="top">Cushing syndrome</td>
<td align="left" valign="top">0.1356</td>
</tr>
<tr>
<td align="left" valign="top">Natural killer cell mediated cytotoxicity</td>
<td align="left" valign="top">0.1410</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">
<bold>Biosynthesis/Metabolism signaling pathways</bold>
</td>
<td align="left" valign="top"/>
<td align="left" valign="top">
<bold>Adhesion signaling pathways</bold>
</td>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">Sulfur metabolism</td>
<td align="left" valign="top">0.0758</td>
<td align="left" valign="top">Focal adhesion</td>
<td align="left" valign="top">1.39E-05</td>
</tr>
<tr>
<td align="left" valign="top">Galactose metabolism</td>
<td align="left" valign="top">0.0812</td>
<td align="left" valign="top">ECM-receptor interaction</td>
<td align="left" valign="top">0.0002</td>
</tr>
<tr>
<td align="left" valign="top">Glycosaminoglycan degradation</td>
<td align="left" valign="top">0.0905</td>
<td align="left" valign="top">Adherens junction</td>
<td align="left" valign="top">0.0669</td>
</tr>
<tr>
<td align="left" valign="top">Steroid hormone biosynthesis</td>
<td align="left" valign="top">0.1084</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">Starch and sucrose metabolism</td>
<td align="left" valign="top">0.1084</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">Primary bile acid biosynthesis</td>
<td align="left" valign="top">0.1437</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T5" position="float" orientation="portrait">
<label>Table 4</label>
<caption>
<title>up-regulated genes in TNF and apoptosis signaling pathways.</title>
</caption>
<table frame="box" rules="all">
<tbody>
<tr>
<td align="left" valign="top">Apoptosis</td>
<td align="left" valign="top">BCL2, RELA, BIRC3, FADD, GADD45G, TNFRSF1A, NFKBIA, TNFRSF10B, CAPN2, TUBA1C, IL3RA, CTSH, FOS, CASP6, CASP7, TNFRSF10A, PARP4</td>
</tr>
<tr>
<td align="left" valign="top">TNF signaling pathway</td>
<td align="left" valign="top">RELA, BIRC3, FADD, MAP2K3, TNFRSF1A, NFKBIA, CREB3L2, FOS, CASP7, MLKL, IRF1, CEBPB</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T6" position="float" orientation="portrait">
<label>Table 5</label>
<caption>
<title>The 30 down-regulated KEGG signaling pathways.</title>
</caption>
<table frame="box" rules="all">
<thead>
<tr>
<th align="left" valign="top">Pathway Names</th>
<th align="left" valign="top">p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">
<bold>Neuron related signaling pathways</bold>
</td>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">Neuroactive ligand-receptor interaction</td>
<td align="left" valign="top">4.35E-06</td>
</tr>
<tr>
<td align="left" valign="top">Circadian entrainment</td>
<td align="left" valign="top">0.003</td>
</tr>
<tr>
<td align="left" valign="top">Glutamatergic synapse</td>
<td align="left" valign="top">0.009</td>
</tr>
<tr>
<td align="left" valign="top">Synaptic vesicle cycle</td>
<td align="left" valign="top">0.017</td>
</tr>
<tr>
<td align="left" valign="top">SNARE interactions in vesicular transport</td>
<td align="left" valign="top">0.036</td>
</tr>
<tr>
<td align="left" valign="top">Dopaminergic synapse</td>
<td align="left" valign="top">0.040</td>
</tr>
<tr>
<td align="left" valign="top">GABAergic synapse</td>
<td align="left" valign="top">0.148</td>
</tr>
<tr>
<td align="left" valign="top">
<bold>Addiction signaling pathways</bold>
</td>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">Nicotine addiction</td>
<td align="left" valign="top">0.003</td>
</tr>
<tr>
<td align="left" valign="top">Alcoholism</td>
<td align="left" valign="top">0.006</td>
</tr>
<tr>
<td align="left" valign="top">Morphine addiction</td>
<td align="left" valign="top">0.075</td>
</tr>
<tr>
<td align="left" valign="top">
<bold>Fatty acid signaling pathways</bold>
</td>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">Fatty acid elongation</td>
<td align="left" valign="top">0.062</td>
</tr>
<tr>
<td align="left" valign="top">Fatty acid biosynthesis</td>
<td align="left" valign="top">0.132</td>
</tr>
<tr>
<td align="left" valign="top">
<bold>Signaling transduction pathways</bold>
</td>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">cAMP signaling pathway</td>
<td align="left" valign="top">0.023</td>
</tr>
<tr>
<td align="left" valign="top">mTOR signaling pathway</td>
<td align="left" valign="top">0.023</td>
</tr>
<tr>
<td align="left" valign="top">Ras signaling pathway</td>
<td align="left" valign="top">0.083</td>
</tr>
<tr>
<td align="left" valign="top">
<bold>Infection signaling pathways</bold>
</td>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">Oxidative phosphorylation</td>
<td align="left" valign="top">4.05E-05</td>
</tr>
<tr>
<td align="left" valign="top">Vibrio cholerae infection</td>
<td align="left" valign="top">0.0002</td>
</tr>
<tr>
<td align="left" valign="top">Amphetamine addiction</td>
<td align="left" valign="top">0.0009</td>
</tr>
<tr>
<td align="left" valign="top">Epithelial cell signaling in Helicobacter pylori infection</td>
<td align="left" valign="top">0.0009</td>
</tr>
<tr>
<td align="left" valign="top">
<bold>Metabolism signaling pathways</bold>
</td>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">Taurine and hypotaurine metabolism</td>
<td align="left" valign="top">0.038</td>
</tr>
<tr>
<td align="left" valign="top">Butanoate metabolism</td>
<td align="left" valign="top">0.046</td>
</tr>
<tr>
<td align="left" valign="top">Cysteine and methionine metabolism</td>
<td align="left" valign="top">0.060</td>
</tr>
<tr>
<td align="left" valign="top">Retinol metabolism</td>
<td align="left" valign="top">0.088</td>
</tr>
<tr>
<td align="left" valign="top">
<bold>Other signaling pathways</bold>
</td>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">Valine, leucine and isoleucine biosynthesis</td>
<td align="left" valign="top">0.007</td>
</tr>
<tr>
<td align="left" valign="top">Phagosome</td>
<td align="left" valign="top">0.018</td>
</tr>
<tr>
<td align="left" valign="top">Retrograde endocannabinoid signaling</td>
<td align="left" valign="top">0.056</td>
</tr>
<tr>
<td align="left" valign="top">Long-term potentiation</td>
<td align="left" valign="top">0.071</td>
</tr>
<tr>
<td align="left" valign="top">Salivary secretion</td>
<td align="left" valign="top">0.078</td>
</tr>
<tr>
<td align="left" valign="top">Gastric acid secretion</td>
<td align="left" valign="top">0.083</td>
</tr>
<tr>
<td align="left" valign="top">Phototransduction</td>
<td align="left" valign="top">0.086</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
